Effects of vitreomacular adhesion on ranibizumab treatment in Japanese patients with age-related macular degeneration

Japanese Journal of Ophthalmology

Volumn 58, Issue 5, 2014, Pages 443-447

  Nomura, Yoko ^a   Takahashi, Hidenori ^a   Tan, Xue ^a   Fujimura, Shigeto ^a   Obata, Ryo ^a   Yanagi, Yasuo ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Age related macular degeneration; Ranibizumab; Vitreomacular adhesion

Indexed keywords

ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; RANIBIZUMAB; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGED; ANTAGONISTS AND INHIBITORS; COMPARATIVE STUDY; COMPLICATION; FEMALE; HUMAN; INTRAVITREAL DRUG ADMINISTRATION; MALE; MIDDLE AGED; OPTICAL COHERENCE TOMOGRAPHY; PATHOLOGY; PHYSIOLOGY; RETINAL DISEASES; RETROSPECTIVE STUDY; TISSUE ADHESION; TREATMENT OUTCOME; VERY ELDERLY; VISUAL ACUITY; VITREOUS BODY; WET MACULAR DEGENERATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; RETINAL DISEASES; RETROSPECTIVE STUDIES; TISSUE ADHESIONS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY; WET MACULAR DEGENERATION;

EID: 84925884031     PISSN: 00215155     EISSN: 16132246     Source Type: Journal    
DOI: 10.1007/s10384-014-0333-5     Document Type: Article

References (20)

1. Weber-Krause B, Eckardt U. Incidence of posterior vitreous detachment in eyes with and without age-related macular degeneration: an ultrasonic study [in German]. Ophthalmologe. 1996;93:660–5.
2. Ondes F, Yilmaz G, Acar MA, Unlu N, Kocaoglan H, Arsan AK. Role of the vitreous in age-related macular degeneration. Jpn J Ophthalmol. 2000;44:91–3.
3. Quaranta-El Maftouhi M, Mauget-Faysse M. Anomalous vitreoretinal adhesions in patients with exudative age-related macular degeneration: an OCT study. Eur J Ophthalmol. 2006;16:134–7.
4. Krebs I, Brannath W, Glittenberg C, Zeiler F, Sebag J, Binder S. Posterior vitreomacular adhesion: a potential risk factor for exudative age-related macular degeneration? Am J Ophthalmol. 2007;144:741–6.
5. Robison CD, Krebs I, Binder S, Barbazetto IA, Kotsolis AI, Yannuzzi LA, et al. Vitreomacular adhesion in active and end-stage age-related macular degeneration. Am J Ophthalmol. 2009;148(79–82):e72.
6. Nomura Y, Ueta T, Iriyama A, Inoue Y, Obata R, Tamaki Y, et al. Vitreomacular interface in typical exudative age-related macular degeneration and polypoidal choroidal vasculopathy. Ophthalmology. 2011;118:853–9.
7. Mojana F, Cheng L, Bartsch DU, Silva GA, Kozak I, Nigam N, et al. The role of abnormal vitreomacular adhesion in age-related macular degeneration: spectral optical coherence tomography and surgical results. Am J Ophthalmol. 2008;146:218–27.
8. Lee SJ, Koh HJ. Effects of vitreomacular adhesion on anti-vascular endothelial growth factor treatment for exudative age-related macular degeneration. Ophthalmology. 2011;118:101–10.
9. Cho HJ, Baek JS, Lee DW, Cho SW, Kim CG, Kim JW. Effects of vitreomacular adhesion on anti-vascular endothelial growth factor treatment for polypoidal choroidal vasculopathy. Retina. 2013;33:2126–32.
10. Mayr-Sponer U, Waldstein SM, Kundi M, Ritter M, Golbaz I, Heiling U, et al. Influence of the vitreomacular interface on outcomes of ranibizumab therapy in neovascular age-related macular degeneration. Ophthalmology. 2013;120:2620–9.
11. Uney GO, Unlu N, Acar MA, Hazirolan D, Altiparmak UE, Yalniz-Akkaya Z, et al. Role of posterior vitreous detachment on outcome of anti-vascular endothelial growth factor treatment in age-related macular degeneration. Retina. 2014;34:32–7.
12. Sho K, Takahashi K, Yamada H, Wada M, Nagai Y, Otsuji T, et al. Polypoidal choroidal vasculopathy: incidence, demographic features, and clinical characteristics. Arch Ophthalmol. 2003;121:1392–6.
13. Obata R, Yanagi Y, Kami J, Takahashi H, Inoue Y, Tamaki Y. Polypoidal choroidal vasculopathy and retinochoroidal anastomosis in Japanese patients eligible for photodynamic therapy for exudative age-related macular degeneration. Jpn J Ophthalmol. 2006;50:354–60.
14. Maruko I, Iida T, Saito M, Nagayama D, Saito K. Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol. 2007;144:15–22.
15. Iranmanesh R, Eandi CM, Peiretti E, Klais CM, Garuti S, Goldberg DE, et al. The nature and frequency of neovascular age-related macular degeneration. Eur J Ophthalmol. 2007;17:75–83.
16. Duker JS, Kaiser PK, Binder S, de Smet MD, Gaudric A, Reichel E, et al. The International Vitreomacular Traction Study Group classification of vitreomacular adhesion, traction, and macular hole. Ophthalmology. 2013;120:2611–9.
17. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897–908.
18. Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012;119:1399–411.
19. Williams TA, Blyth CP. Outcome of ranibizumab treatment in neovascular age related macula degeneration in eyes with baseline visual acuity better than 6/12. Eye (Lond). 2011;25:1617–21.
20. Terao R, Yuda K, Kure K, Inoue T, Ohtsu H, Yanagi Y. Effect of vitreomacular adhesion on antivascular endothelial growth factor therapy for macular edema secondary to branch retinal vein occlusion. Jpn J Ophthalmol. 2014;58:139–45.